224 related articles for article (PubMed ID: 24377525)
1. FBW7 upregulation enhances cisplatin cytotoxicity in non- small cell lung cancer cells.
Yu HG; Wei W; Xia LH; Han WL; Zhao P; Wu SJ; Li WD; Chen W
Asian Pac J Cancer Prev; 2013; 14(11):6321-6. PubMed ID: 24377525
[TBL] [Abstract][Full Text] [Related]
2. FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.
Song Y; Zhou X; Bai W; Ma X
Tumour Biol; 2015 Jun; 36(6):4197-202. PubMed ID: 25586348
[TBL] [Abstract][Full Text] [Related]
3. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition.
Yu J; Zhang W; Gao F; Liu YX; Chen ZY; Cheng LY; Xie SF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2014 Apr; 13(2):184-91. PubMed ID: 24686546
[TBL] [Abstract][Full Text] [Related]
4. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Ye M; Zhang Y; Zhang X; Zhang J; Jing P; Cao L; Li N; Li X; Yao L; Zhang J; Zhang J
Cancer Res; 2017 Jul; 77(13):3527-3539. PubMed ID: 28522751
[TBL] [Abstract][Full Text] [Related]
5. FBW7 loss promotes epithelial-to-mesenchymal transition in non-small cell lung cancer through the stabilization of Snail protein.
Zhang Y; Zhang X; Ye M; Jing P; Xiong J; Han Z; Kong J; Li M; Lai X; Chang N; Zhang J; Zhang J
Cancer Lett; 2018 Apr; 419():75-83. PubMed ID: 29355657
[TBL] [Abstract][Full Text] [Related]
6. MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7.
Xiang J; Hang JB; Che JM; Li HC
Int J Clin Exp Pathol; 2015; 8(8):9147-53. PubMed ID: 26464659
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin sensitivity is enhanced in non-small cell lung cancer cells by regulating epithelial-mesenchymal transition through inhibition of eukaryotic translation initiation factor 5A2.
Xu G; Yu H; Shi X; Sun L; Zhou Q; Zheng D; Shi H; Li N; Zhang X; Shao G
BMC Pulm Med; 2014 Nov; 14():174. PubMed ID: 25380840
[TBL] [Abstract][Full Text] [Related]
8. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
9. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
Yokobori T; Yokoyama Y; Mogi A; Endoh H; Altan B; Kosaka T; Yamaki E; Yajima T; Tomizawa K; Azuma Y; Onozato R; Miyazaki T; Tanaka S; Kuwano H
Mol Cancer Res; 2014 Jan; 12(1):32-7. PubMed ID: 24165483
[TBL] [Abstract][Full Text] [Related]
10. BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via β-catenin pathway.
Zhang Y; Zhang Q; Chen H; Wang C
Life Sci; 2018 Sep; 208():284-294. PubMed ID: 30009824
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.
Ye Z; Yin S; Su Z; Bai M; Zhang H; Hei Z; Cai S
Oncotarget; 2016 Jun; 7(25):37524-37535. PubMed ID: 27229528
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7.
Xu Y; Sengupta T; Kukreja L; Minella AC
J Biol Chem; 2010 Nov; 285(45):34439-46. PubMed ID: 20826802
[TBL] [Abstract][Full Text] [Related]
13. Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study.
Baghbani E; Noorolyai S; Rahmani S; Shanehbandi D; Shadbad MA; Aghebati-Maleki L; Mokhtarzadeh A; Brunetti O; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Jan; 145():112370. PubMed ID: 34862113
[TBL] [Abstract][Full Text] [Related]
14. Garcinol Sensitizes NSCLC Cells to Standard Therapies by Regulating EMT-Modulating miRNAs.
Farhan M; Malik A; Ullah MF; Afaq S; Faisal M; Farooqi AA; Biersack B; Schobert R; Ahmad A
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30781783
[TBL] [Abstract][Full Text] [Related]
15. miR-324-5p upregulation potentiates resistance to cisplatin by targeting FBXO11 signalling in non-small cell lung cancer cells.
Ba Z; Zhou Y; Yang Z; Xu J; Zhang X
J Biochem; 2019 Dec; 166(6):517-527. PubMed ID: 31778188
[TBL] [Abstract][Full Text] [Related]
16. Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.
Tièche CC; Peng RW; Dorn P; Froment L; Schmid RA; Marti TM
BMC Cancer; 2016 Feb; 16():125. PubMed ID: 26895954
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor functions of FBW7 in cancer development and progression.
Wang Z; Inuzuka H; Zhong J; Wan L; Fukushima H; Sarkar FH; Wei W
FEBS Lett; 2012 May; 586(10):1409-18. PubMed ID: 22673505
[TBL] [Abstract][Full Text] [Related]
18. E3 ubiquitin ligase Hakai regulates cell growth and invasion, and increases the chemosensitivity to cisplatin in non‑small‑cell lung cancer cells.
Liu Z; Wu Y; Tao Z; Ma L
Int J Mol Med; 2018 Aug; 42(2):1145-1151. PubMed ID: 29786107
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
Xia Y; He Z; Liu B; Wang P; Chen Y
Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
[TBL] [Abstract][Full Text] [Related]
20. Impact of Brachyury on epithelial-mesenchymal transitions and chemosensitivity in non-small cell lung cancer.
Xu K; Liu B; Liu Y
Mol Med Rep; 2015 Jul; 12(1):995-1001. PubMed ID: 25683840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
